前往研报中心>>
TROP2 ADC updates reinforce sac-TMT’s global positioning
内容摘要
Recent Datroway and Trodelvy updates provide a favorable read-through to Kelun-Biotech’s sac-TMT. In NSCLC, Datroway’s key Ph3 readouts in 1L NSCLC are concentrated in 1H27. Trodelvy’s US$2bn annualized run rate validates the commercial potential of the TROP2 ADC class, with upcoming ASCENT-GYN readout offering an important read-across in endometrial cancer (EC). Meanwhile, the industry-wide move to combine ADCs with PD-(L)1/VEGF bsAb supports sac-TMT’s combination strategy. With the first positive global Ph3 readout from the TroFuse program, continued data readouts from 18 ongoing global Ph3 trials, MSD’s expanding development strategy, and positive China Ph3 results in first-line NSCLC across the PD-L1 spectrum, we believe sac-TMT remains strongly positioned competitively. We maintain BUY rating on Kelun Biotech with a target price of HK$645.62.
Attention on Datroway’s Ph3 readouts in 1L NSCLC in 1H27. In NSCLC, despite its earlier setback in 2L+ disease, Datroway has four Ph3 readouts expected in 1H27, including three in 1L NSCLC (AVANZAR and TROPION-Lung07/-Lung08) and one in 2L EGFR-mutant NSCLC, with the AVANZAR readout being pushed further into 1H27. Together, these studies should provide important insight into the role of TROP2 ADCs in NSCLC and help shape subsequent clinical development strategies. AstraZeneca’s investment in Summit and collaboration to evaluate ADCs with ivonescimab supports the ADC plus PD-(L)1/VEGF strategy. Meanwhile, Kelun Biotech’s positive OptiTROP-Lung05/-Lung06 readouts underpin sac-TMT’s activity in 1L NSCLC across PD-L1 spectrum and MSD’s global developments.
Trodelvy validates TROP2 ADC adoption with ASCENT-GYN as the next near-term read-across for sac-TMT. Trodelvy’s strong commercial momentum continues to validate the TROP2 ADC class. Sales reached US$506mn in 3Q26, up 42% YoY and 11% QoQ, bringing the annualized run rate to US$2.0bn, with growth driven by 1L TNBC and 3L+ HR+/HER2- breast cancer. Ph3 ASCENT-GYN data in EC, expected by end-2026, will offer an important read-across to sac-TMT’s positive global TroFuse-005 data. Gilead also plans to evaluate Trodelvy plus BioNTech’s pumitamig (PD-L1×VEGF-A) in 1L TNBC.
Sac-TMT combines global validation with lifecycle optionality. TroFuse-005 is the first positive global Ph3 study of sac-TMT and supported FDA priority review in EC (PDUFA date of 15 Jun 2027). Beyond EC, multiple global Ph3 trials are ongoing in NSCLC, while MSD is planning additional global Ph3 trials of sac-TMT in combination with either Keytruda or MK-2010 (PD-1/VEGF bsAb) in 1L NSCLC. With multiple global Ph3 readouts expected across 2027–28, we believe sac-TMT is well positioned to evolve into a multi-tumor global franchise as MSD’s cornerstone asset.
Maintain BUY. Datroway’s later readout schedule in 1L NSCLC warrants close attention, while Trodelvy’s strong commercial trajectory provides increasing proof of class adoption. Near-term watchpoints include the ASCENT-GYN readout around end-2026, the sac-TMT EC approval, further TroFuse Ph3 readouts in 2027 and initiation of MK-2010 plus sac-TMT Ph3 combinations in 1H27. Factoring in the smooth development of sac-TMT, we raise our DCF-based TP from HK$642.29 to HK$645.62 (WACC 8.69%, terminal growth rate 3.5%).
回复 0 条,有 0 人参与

我有话说

禁止发表不文明、攻击性、及法律禁止言语;

还可以输入 140 个字符  
以下网友评论只代表同花顺网友的个人观点,不代表同花顺金融服务网观点。